Microsatellite analysis in serum DNA as a diagnostic tool for distinction of patients with unknown pancreatic masses.
Standard
Microsatellite analysis in serum DNA as a diagnostic tool for distinction of patients with unknown pancreatic masses. / Wachowiak, Robin; Kaifi, Jussuf; Schwarzenbach, Heidi; Yekebas, Emre F.; Merkert, Petra; Schurr, Paulus; Hansen, Bente; Reichelt, Uta; Strate, Tim; Pantel, Klaus; Izbicki, Jakob R.
In: DIAGN MOL PATHOL, Vol. 16, No. 3, 3, 2007, p. 174-178.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Microsatellite analysis in serum DNA as a diagnostic tool for distinction of patients with unknown pancreatic masses.
AU - Wachowiak, Robin
AU - Kaifi, Jussuf
AU - Schwarzenbach, Heidi
AU - Yekebas, Emre F.
AU - Merkert, Petra
AU - Schurr, Paulus
AU - Hansen, Bente
AU - Reichelt, Uta
AU - Strate, Tim
AU - Pantel, Klaus
AU - Izbicki, Jakob R.
PY - 2007
Y1 - 2007
N2 - The clinical distinction between cancer and chronic pancreatitis is difficult in patients with pancreatic masses. To test whether detection of aberrant serum DNA could assist in this important differential diagnosis, we tested a panel of 12 microsatellitemarkers from chromosomes 17p, 17q, 13q, 9p, 5q, and 2p in the blood of 35 pancreatic cancer patients, 22 patients with chronic pancreatitis, and 20 healthy individuals. An average of 2.8 loss of heterozygosity (LOH) was found in 32 of 35 cancer patients of whom 30 (86%) had 2 or more LOH. LOH was also found in 7 of 22 pancreatitis patients but all these patients had only 1 LOH. No LOH was detected in healthy donors of comparable age. These data suggest that LOH analysis may be a substantial help for diagnosing pancreatic masses. An extension of the panel, perhaps in combination with a better selection of markers may further improve this assay.
AB - The clinical distinction between cancer and chronic pancreatitis is difficult in patients with pancreatic masses. To test whether detection of aberrant serum DNA could assist in this important differential diagnosis, we tested a panel of 12 microsatellitemarkers from chromosomes 17p, 17q, 13q, 9p, 5q, and 2p in the blood of 35 pancreatic cancer patients, 22 patients with chronic pancreatitis, and 20 healthy individuals. An average of 2.8 loss of heterozygosity (LOH) was found in 32 of 35 cancer patients of whom 30 (86%) had 2 or more LOH. LOH was also found in 7 of 22 pancreatitis patients but all these patients had only 1 LOH. No LOH was detected in healthy donors of comparable age. These data suggest that LOH analysis may be a substantial help for diagnosing pancreatic masses. An extension of the panel, perhaps in combination with a better selection of markers may further improve this assay.
M3 - SCORING: Zeitschriftenaufsatz
VL - 16
SP - 174
EP - 178
JO - DIAGN MOL PATHOL
JF - DIAGN MOL PATHOL
SN - 1052-9551
IS - 3
M1 - 3
ER -